The competitive cost of antibiotic resistance in Mycobacterium tuberculosis

Science

Volumn 312, Issue 5782, 2006, Pages 1944-1946

  Gagneux, Sebastien ^a,b   Long, Clara Davis ^a   Small, Peter M ^b,c   Van, Tran ^a   Schoolnik, Gary K ^a   Bohannan, Brendan J M ^a  

^a STANFORD UNIVERSITY   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDEMIOLOGY; MATHEMATICAL MODELS; PATIENT TREATMENT; STRAIN;

CLINICAL ISOLATES; MULTIDRUG-RESISTANT; MYCOBACTERIUM TUBERCULOSIS; STRAIN GENETIC BACKGROUND;

ANTIBIOTICS;

ANTIBIOTIC RESISTANCE; COST; EPIDEMIC; FITNESS; FUTURE PROSPECT; GENETIC DIFFERENTIATION; LABORATORY METHOD; MUTATION; NUMERICAL METHOD; TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIUM MUTANT; COST BENEFIT ANALYSIS; EPIDEMIC; GENE MUTATION; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; MUTATION; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 33745615117     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1124410     Document Type: Article

References (29)

1. S. R. Palumbi, Science 293, 1786 (2001).
2. T. M. File Jr., Chest 115, 35 (1999).
3. D. I. Andersson, B. R. Levin, Curr. Opin. Microbiol. 2, 489 (1999).
4. M. G. Reynolds, Genetics 156, 1471 (2000).
5. S. Maisnier-Patin, D. I. Andersson, Res. Microbiol. 155, 360 (2004).
6. F. M. Cohan, E. C. King, P. Zawadzki, Evol. Int. J. Org. Evol. 48, 81 (1994).
7. B. Bjorkholm et al., Proc. Natl. Acad. Sci. U.S.A. 98, 14607 (2001).
8. S. J. Schrag, V. Perrot, Nature 381, 120 (1996).
9. E. C. Böttger, B. Springer, M. Pletschette, P. Sander, Nat. Med. 4, 1343 (1998).
10. T. A. Wichelhaus et al., Antimicrob. Agents Chemother. 46, 3381 (2002).
11. P. Sander et al., Antimicrob. Agents Chemother. 46, 1204 (2002).
12. O. J. Billington, T. D. McHugh, S. H. Gillespie, Antimicrob. Agents Chemother. 43, 1866 (1999).
13. World Health Organization, Anti-Tuberculosis Drug Resistance in the World-Third Global Report, G. T. C. Program, Ed. (World Health Organization, Geneva, 2004).
14. J. S. Mukherjee et al., Lancet 363, 474 (2004).
15. C. Dye, M. A. Espinal, Proc. R. Soc. London Ser. B 268, 45 (2001).
16. S. M. Blower, T. Chou, Nat. Med. 10, 1111 (2004).
17. T. Cohen, M. Murray, Nat. Med. 10, 1117 (2004).
18. C. Dye, B. G. Williams, M. A. Espinal, M. C. Raviglione, Science 295, 2042 (2002).
19. S. Ramaswamy, J. M. Musser, Tuber. Lung Dis. 79, 3 (1998).
20. D. H. Mariam, Y. Mengistu, S. E. Hoffner, D. I. Andersson, Antimicrob. Agents Chemother. 48, 1289 (2004).
21. R. S. Lenski, M. R. Rose, S. C. Simpson, S. C. Tadler, Am. Nat. 138, 1315 (1991).
22. L. Baker, T. Brown, M. C. Maiden, F. Drobniewski, Emerg. Infect. Dis. 10, 1568 (2004).
23. R. D. Fleischmann et al., J. Bacteriol. 184, 5479 (2002).
24. S. Gagneux et al., Proc. Natl. Acad. Sci. U.S.A. 103, 2869 (2006).
25. A. G. Tsolaki et al., J. Clin. Microbiol. 43, 3185 (2005).
26. P. F. Barnes, M. D. Cave, N. Engl. J. Med. 349, 1149 (2003).
27. F. A. Post et al., J. Infect. Dis. 190, 99 (2004).
28. D. M. O'Sullivan, T. D. McHugh, S. H. Gillespie, J. Antimicrob. Chemother. 56, 674 (2005); published online 6 April 2005 (10.1093/jac/dki069).
29. We thank K. Kremer and A. Ponce de Leon for providing clinical strains. This research was supported by the NIH and the Wellcome Trust. S.G. was supported by the Swiss National Science Foundation and the Novartis Foundation.